# Acacia Research Corp: Form 10-Q for the period ended Sep 30, 2021

- Company: [Acacia Research Corp](/companies/actg.md) (CIK 934549)
- Form: 10-Q
- Filed: 2021-11-15
- Accepted by EDGAR: Nov 15, 2021, 16:11 ET
- Period: 2021-09-30
- Accession: 0001683168-21-005701
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/934549/000168316821005701/acacia_i10q-93021.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/934549/000168316821005701/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $1.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $24.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-07-01 to 2021-09-30 | $4.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2021-01-01 to 2021-09-30 | $18.5m | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$12.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$16.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | $11.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | $531.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | $89.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$55.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | $0.86 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | −$1.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | $1.49 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | −$1.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 93,081,502 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 48,759,873 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$7.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $67.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2021-01-01 to 2021-09-30 | $785.0k | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2021-01-01 to 2021-09-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-09-30 | $218.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $669.4m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $749.8m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $204.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $500.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $223.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 62,523 characters.

*The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and the related notes included in Part I, Item1 of this Quarterly Report on Form10-Q for the three and nine months ended September 30, 2021, or this Report. This discussion and analysis contains forward-looking statements that are based on our current expectations and reflect our plans, estimates and anticipated future financial performance. See the section of this Report entitled “Cautionary Statement Regarding Forward-Looking Statements” for additional information. These statements involve numerous risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those set forth in “Risk Factors” in Part II, Item1A. of this Report.*

### General

Acacia Research Corporation (the “Company,” “we,” “us,” or “our”) acquires businesses and operating assets that we believe to be undervalued and where we believe we can leverage our resources and skill sets to realize and unlock value. We leverage our (i) access to flexible capital that can be deployed unconditionally, (ii) expertise in corporate governance and operational restructuring, (iii) willingness to invest in out of favor industries and businesses that suffer from a complexity discount and untangle complex, multi-factor situations, and (iv) expertise and relationships in certain sectors, to complete strategic acquisitions of businesses, divisions, and/or assets with a focus on mature technology, healthcare, industrial and certain financial segments. We seek to identify opportunities where we believe we are advantaged buyers, where we can avoid structured sale processes and create the opportunity to purchase businesses, divisions and/or assets of companies at an attractive price due to our unique capabilities, relationships, or expertise, or where we believe the target would be worth more to us than to other buyers.

We operate our business based on three key principles of People, Process and Performance and have built a management team with identified expertise in Research, Execution and Operation of our targeted acquisitions.

We utilized these skill sets and resources to acquire a portfolio of equity securities of public and private life science businesses, or the “Life Sciences Portfolio”, in June 2020. As of September 30, 2021, we have monetized a portion of the portfolio while retaining an interest in a number of operating businesses, including a controlling interest in one of the companies in the portfolio. Further, some of the businesses in which we continue to hold an interest generate revenues through the receipt of royalties.

We also operate our legacy business of investing in intellectual property, or IP, and related absolute return assets and engaging in the licensing and enforcement of patented technologies. We partner with inventors and patent owners, from small entities to large corporations, applying our legal and technology expertise to patent assets to unlock the financial value in their patented inventions. We are an intermediary in the patent marketplace, bridging the gap between invention and application, and facilitating efficiency in connection with the monetization of patent assets.

We generate revenues and related cash flows from the granting of IP rights for the use of patented technologies that our operating subsidiaries control or own. We assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented inventions from unauthorized use, the generation of licensing revenue from users of their patented technologies and, where necessary, with the enforcement against unauthorized users of their patented technologies through the filing of patent infringement litigation. Currently, on a consolidated basis, our operating subsidiaries own or control the rights to multiple patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a variety of industries.

We have established a proven track record of licensing and enforcement success with over 1,600 license agreements executed to date, across nearly 200 patent portfolio licensing and enforcement programs. To date, we have generated gross licensing revenue of approximately $1.7 billion, and have returned $828.7 million to our patent partners.

### COVID-19 Pandemic

The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. While the Company does not expect the current situation to present direct risks to its business, and it has not had a material impact to date, the COVID-19 pandemic could adversely impact the Company’s operations, as well as the operations of its licensees and other business partners. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, results of operations and financial condition.

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on March 27, 2020. The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer’s social security payments, net operating loss utilization and carryback periods and modifications to the net interest deduction limitations. The CARES Act has not had a material impact on the Company’s income tax provision.

On December 27, 2020, the President of the United States signed the Consolidated Appropriations Act, 2021 (“Consolidated Appropriations Act”) into law. The Consolidated Appropriations Act is intended to enhance and expand certain provisions of the CARES Act, allows for the deductions of expenses related to the Payroll Protection Program funds received by companies, and provides an update to meals and entertainment expensing for 2021. The Consolidated Appropriations Act did not have a material impact to the Company’s income tax provision for 2020. The Company will continue to evaluate the impact of the Consolidated Appropriations Act on its financial position, results of operations and cash flows, if any.

On March 11, 2021 the United States enacted the American Rescue Plan Act of 2021. This Act includes various income and payroll tax measures. The Company does not expect a material impact of the American Rescue Plan on its consolidated financial statements and related disclosures.

### Executive Summary

#### Overview

Our operating activities during the periods presented were focused on the continued operation of our patent licensing and enforcement business, including the continued pursuit of our ongoing patent licensing and enforcement programs.

#### Patent Licensing and Enforcement

- *Patent Litigation Trial Dates and Related Trials*

As of the date of this report, our operating subsidiaries have nine pending patent infringement cases with scheduled trial dates in the next twelve months. Patent infringement trials are components of our overall patent licensing process and are one of many factors that contribute to possible future revenue generating opportunities for us. Scheduled trial dates, as promulgated by the respective court, merely provide an indication of when, in future periods, the trials may occur according to the court’s scheduling calendar at a specific point in time. A court may change previously scheduled trial dates. In fact, courts often reschedule trial dates for various reasons that are unrelated to the underlying patent assets and typically for reasons that are beyond our control. While scheduled trial dates provide an indication of the timing of possible future revenue generating opportunities for us, the trials themselves and the immediately preceding periods represent the possible future revenue generating opportunities. These future opportunities can result in varying outcomes. In fact, it is difficult to predict the outcome of patent enforcement litigation at the trial level and outcomes can be unfavorable. It can be difficult to understand complex patented technologies, and as a result, this may lead to a higher rate of unfavorable litigation outcomes. Moreover, in the event of a favorable outcome, there is, in our experience, a higher rate of successful appeals in patent enforcement litigation than more standard business litigation. Such appeals are expensive and time consuming, resulting in increased costs and a potential for delayed or foregone revenue opportunities in the event of modification or reversal of favorable outcomes. Although we diligently pursue enforcement litigation, we cannot predict with reliability the decisions made by juries and trial courts. Please refer to Part II, Item 1A. “Risk Factors” for additional information regarding trials, patent litigation and related risks.

- *Litigation and Licensing Expense*

We expect patent-related legal expenses to continue to fluctuate from period to period based on the factors summarized herein, in connection with future trial dates, international enforcement, strategic patent portfolio prosecution and our current and future patent portfolio investment, prosecution, licensing and enforcement activities. The pursuit of enforcement actions in connection with our licensing and enforcement programs can involve certain risks and uncertainties, including the following:

- Increases in patent-related legal expenses associated with patent infringement litigation, including, but not limited to, increases in costs billed by outside legal counsel for discovery, depositions, economic analyses, damages assessments, expert witnesses and other consultants, re-exam and inter partes review costs, case-related audio/video presentations and other litigation support and administrative costs, could increase our operating costs and decrease our profit generating opportunities;
- Our patented technologies and enforcement actions are complex and, as a result, we may be required to appeal adverse decisions by trial courts in order to successfully enforce our patents. Moreover, such appeals may not be successful;
- New legislation, regulations or rules related to enforcement actions, including any fee or cost shifting provisions, could significantly increase our operating costs and decrease our profit generating opportunities. Increased focus on the growing number of patent-related lawsuits may result in legislative changes which increase our costs and related risks of asserting patent enforcement actions;
- Courts may rule that our subsidiaries have violated certain statutory, regulatory, federal, local or governing rules or standards by pursuing such enforcement actions, which may expose us and our operating subsidiaries to material liabilities, which could harm our operating results and our financial position;
- The complexity of negotiations and potential magnitude of exposure for potential infringers associated with higher quality patent portfolios may lead to increased intervals of time between the filing of litigation and potential revenue events (i.e., markman dates, trial dates), which may lead to increased legal expenses, consistent with the higher revenue potential of such portfolios; and
- Fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above could harm our operating results and our financial position.

#### Investments in Patent Portfolios

With respect to our licensing, enforcement and overall business, neither we nor our operating subsidiaries invent new technologies or products; rather, we depend upon the identification and investment in patents, inventions and companies that own IP through our relationships with inventors, universities, research institutions, technology companies and others. If our operating subsidiaries are unable to maintain those relationships and identify and grow new relationships, then we may not be able to identify new technology-based patent opportunities for sustainable revenue and /or revenue growth.

Our current or future relationships may not provide the volume or quality of technologies necessary to sustain our licensing, enforcement and overall business. In some cases, universities and other technology sources compete against us as they seek to develop and commercialize technologies. Universities may receive financing for basic research in exchange for the exclusive right to commercialize resulting inventions. These and other strategies employed by potential partners may reduce the number of technology sources and potential clients to whom we can market our solutions. If we are unable to maintain current relationships and sources of technology or to secure new relationships and sources of technology, such inability may have a material adverse effect on our revenues, operating results, financial condition and ability to maintain our licensing and enforcement business.

#### Patent Portfolio Intake

One of the significant challenges in our industry continues to be quality patent intake due to the challenges and complexity associated with the current patent environment.

During the nine months ended September 30, 2021, we acquired one new patent portfolio consisting of Wi-Fi 6 standard essential patents. The patents and patent rights acquired during the nine months ended September 30, 2021 have estimated economic useful lives of approximately five years. In fiscal year 2020, we acquired five patent portfolios.

#### Starboard Securities

In 2019, as part of its strategy to grow, the Company began evaluating a wide range of strategic opportunities that culminated in the strategic investment in the Company by certain funds and accounts, or the Buyers, affiliated with, or managed by, Starboard Value LP, or Starboard. On November 18, 2019, the Company entered into a Securities Purchase Agreement with Starboard and the Buyers, or the Securities Purchase Agreement, pursuant to which the Buyers purchased (i) 350,000 shares of the Company’s newly designated Series A Convertible Preferred Stock, or Series A Preferred Stock, at an aggregate purchase price of $35.0 million, and warrants to purchase up to 5 million shares of the Company’s common stock, or Series A Warrants. The Securities Purchase Agreements also established the terms of certain senior secured notes, or Notes, and additional warrants, or the Series B Warrants, which may be issued to the Buyers in the future. Refer to Notes 2 and 6 to the consolidated financial statements elsewhere herein for additional information related to the Series A Preferred Stock, Series A Warrants and Series B Warrants. In connection with the Buyer’s investment, Starboard was granted certain corporate governance rights, including the right to appoint Jonathan Sagal, Managing Director of Starboard, as a director of the Company and recommend two additional directors for appointment to our Board of Directors. The investment by the Buyers is referred to herein as the “Starboard Investment,” and the Series A Preferred Stock, Series A Warrants and Series B Warrants are referred to herein as, collectively, the “Starboard Securities.”

On February 14, 2020, the Company’s stockholders approved, for purposes of Nasdaq Rules 5635(b) and 5635(d), as applicable, (i) the voting of the Series A Preferred Stock on an as-converted basis and (ii) the issuance of the maximum number of shares of common stock issuable in connection with the potential future (A) conversion of the Series A Preferred Stock and (B) exercise of the Series A and Series B Warrants, in each case, without giving effect to the exchange cap set forth in the Series A Preferred Stock Certificate of Designations and in the Series A Warrants, issued pursuant to the Securities Purchase Agreement dated November 18, 2019. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information. The Company’s stockholders also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock by 200 million shares, from 100 million shares to 300 million shares.

On February 25, 2020, pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, the Company issued Series B Warrants to purchase up to 100 million shares of the Company’s common stock at an exercise price of either (i) $5.25 per share, if exercising by cash payment, or (ii) $3.65 per share, if exercising by cancellation of a portion of Notes. The Company issued the Series B Warrants for an aggregate purchase price of $4.6 million. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information.

Pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, on June 4, 2020, the Company issued $115.0 million in Notes to the Buyers. Also on June 4, 2020, in connection with the issuance of the Notes, the Company entered into a Supplemental Agreement with Starboard, or the Supplemental Agreement, through which, the Company agreed to redeem $80.0 million aggregate principal amount of the Notes by September 30, 2020, and $35.0 million aggregate principal amount of the Notes by December 31, 2020, resulting in the total principal outstanding being paid by December 31, 2020. Per the Supplemental Agreement, interest is payable semiannually at a rate of 6.00% per annum, and in an event of default, the interest rate is increased to 10.00% per annum. The Notes outlined certain financial and non-financial covenants. Additionally, all or any portion of the principal amount outstanding under the Notes may, at the election of the holders, be surrendered to the Company for cancellation in payment of the exercise price upon the exercise of the Series B Warrants.

On June 30, 2020, the Company entered into an Exchange Agreement, or the Exchange Agreement, with Merton Acquisition HoldCo LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company, or Merton, and Starboard, on behalf of itself and on behalf of the Buyers, including the holders of the Notes. Pursuant to the Exchange Agreement, the holders of the Notes exchanged the entire outstanding principal amount of the Notes for new senior notes, or the New Notes, issued by Merton and having an aggregate outstanding original principal amount of $115.0 million. The New Notes bear interest at a rate of 6.00% per annum and had a maturity date of December 31, 2020. The New Notes are fully guaranteed by the Company and are secured by an all-assets pledge of the Company and Merton and non-recourse equity pledges of each of the Company’s material subsidiaries. Pursuant to the Exchange Agreement, the New Notes (i) are deemed to be “Notes” for purposes of the Securities Purchase Agreement, (ii) are deemed to be “June 2020 Approved Investment Notes” for purposes of the Supplemental Agreement, and with the Company agreeing to redeem $80.0 million principal amount of the New Notes by September 30, 2020 and $35.0 million principal amount of the New Notes by December 31, 2020, and (iii) are deemed to be “Notes” for the purposes of the Series B Warrants, and therefore may be tendered pursuant to a Note Cancellation under the Series B Warrants on the terms set forth in the Series B Warrants and the New Notes. Delivery of notes in the form of the New Notes will satisfy the delivery of Exchange Notes pursuant to Section 16(i) of the Certificate of Designations of the Company’s Series A Convertible Preferred Stock, par value $0.001 per share. The New Notes will not be deemed to be “Notes” for the purposes of the Registration Rights Agreement, dated as of November 18, 2019, by and between the Company, Starboard and the Buyers.

On January 29, 2021, the Company redeemed $50.0 million of the New Notes and on March 31, 2021, the Company reissued $50.0 million of the New Notes. On June 30, 2021, the Company issued $30.0 million in additional New Notes (the “June 2021 Merton Notes”) and amended the maturity date of the New Notes to October 15, 2021. On September 30, 2021, the Company issued $35.0 million in additional New Notes (the “September 2021 Merton Notes”) and amended the maturity date of the New Notes to December 1, 2021. The June and September 2021 Merton Notes cannot be used to exercise Series B Warrants issued to Starboard Value. The total principal amount outstanding of New Notes as of September 30, 2021 and December 31, 2020 was $180.0 million and $115.0 million, respectively. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information.

#### Equity Securities Portfolio Investment

On April 3, 2020, the Company entered into an Option Agreement with Seller to purchase equity securities in the Life Sciences Portfolio, for an aggregate purchase price of £223.9 million, approximately $277.5 million at the exchange rate on April 3, 2020.

On June 4, 2020, the Company executed the Transaction Agreement between Link Fund Solutions Limited, or Link, Seller, and the Company. Pursuant to the Transaction Agreement, the Company will purchase from Seller and Seller will transfer to the Company the specified equity securities of all companies in the Life Sciences Portfolio at set prices at various future dates. In accordance with the Transaction Agreement, the Company transferred the total purchase price of £223.9 million into an escrow account. Upon the transfer of equity securities in the Life Sciences Portfolio to the Company, the associated funds were released from the escrow account to Seller based on the consideration amount assigned to the equity securities for such Life Sciences Portfolio company in the Transaction Agreement. As of December 31, 2020, all of the equity securities in the Life Sciences Portfolio were transferred to the Company pursuant to the Transaction Agreement. Refer to Note 3 to the consolidated financial statements elsewhere herein for additional information.

#### Operating Activities

Our revenues historically have fluctuated quarterly, and can vary significantly, based on a number of factors including the following:

- the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee;
- the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments;
- fluctuations in the total number of agreements executed each period;
- the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs;
- the relative maturity of licensing programs during the applicable periods;
- other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors;
- the willingness of prospective licensees to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as such infringement cases approached a court determined trial date; and
- fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above.

Our management does not attempt to manage for smooth sequential periodic growth in revenues from period to period, and therefore, periodic results can be uneven. Unlike most operating businesses and industries, licensing revenues not generated in a current period are not necessarily foregone but, depending on whether negotiations, litigation or both continue into subsequent periods, and depending on a number of other factors, such potential revenues may be pushed into subsequent fiscal periods.

Revenues for the nine months ended September 30, 2021 and 2020 included fees from the following technology licensing and enforcement programs:

|  |  |  |  |
| --- | --- | --- | --- |
| • | Bone Wedge technology(1)(2) | • | Wireless Mesh Networking technology(1) |
| • | Flash Memory technology(1) | • | MIPI DSI technology(2) |
| • | Internet search, advertising and cloud computing technology (1)(2) | • | Semiconductor and Memory-Related technology(2) |
| • | Speech codecs used in wireless and wireline systems technology(1)(2) | • | Super Resolutions Microscopy technology(2) |
| • | Wireless Infrastructure and User Equipment technology(1) | • | Video Conferencing technology(2) |
| • | Networking and Security technology(1) | • | Internet radio ad placement(2) |
|  | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ |  |  |
|  | (1) Licensing and enforcement program generating revenue in 2021. |  |  |
|  | (2) Licensing and enforcement program generating revenue in 2020. |  |  |

### Consolidated Results of Operations

#### Summary for the Three and Nine Months Ended September 30, 2021 and 2020

*(In thousands, except percentage change values)*

|  | Three Months Ended September 30, 2021 | 2020 | $ Change | % Change | Nine Months Ended September 30, 2021 | 2020 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $1,582 | $19,466 | $(17,884) | (92%) | $24,785 | $25,399 | $(614) | (2%) |
| Operating costs and expenses | 14,304 | 22,248 | (7,944) | (36%) | 41,539 | 38,498 | 3,041 | 8% |
| Operating loss | (12,722) | (2,782) | (9,940) | 357% | (16,754) | (13,099) | (3,655) | 28% |
| Other income (expense) | 102,337 | 41,213 | 61,124 | 148% | (37,316) | 45,047 | (82,363) | (183%) |
| Income (loss) before income taxes | 89,615 | 38,431 | 51,184 | 133% | (54,070) | 31,948 | (86,018) | (269%) |
| Income tax (expense) benefit | (11) | (83) | 72 | (87%) | (531) | 1,257 | (1,788) | (142%) |
| Net income (loss) attributable to Acacia Research Corporation | 89,604 | 38,348 | 51,256 | 134% | (55,507) | 33,205 | (88,712) | (267%) |

36

### Results of Operations – Three months ended September 30, 2021 compared with the three months ended September 30, 2020

Revenues decreased $17.9 million to $1.6 million for the three months ended September 30, 2021, as compared to $19.5 million in the comparable prior year quarter, primarily due to a decrease in revenues from licensing and enforcement programs during the quarter. New agreements executed were flat quarter over quarter. Refer to “*Investments in Patent Portfolios”* above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.

Income before income taxes was $89.6 million for the three months ended September 30, 2021, as compared to $38.4 million for the three months ended September 30, 2020. The net change was comprised of the change in revenues described above and other changes in operating expenses and other income (expense) as follows:

- Paid-up revenue decreased $18.3 million primarily due to a decrease in average revenue per agreement executed during the quarter, offset by an increase of $401,000 in recurring revenue that provides for quarterly sales-based license fees. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding certain sales-based revenue contracts that provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees.
- Inventor royalties and contingent legal fees, on a combined basis, decreased $11.8 million, from $12.4 million to $565,000, primarily due to the net decrease in revenues described above.
- Litigation and licensing expenses - patents decreased $219,000, from $1.0 million to $782,000, primarily due to a net decrease in litigation support and third-party technical consulting expenses associated with ongoing litigation.
- Amortization of patents expense increased $1.4 million, from $1.2 million to $2.6 million, due to an increase in scheduled amortization resulting from the new portfolios acquired in 2021.
- General and administrative expenses, excluding non-cash stock compensation, increased $2.8 million, from $7.2 million to $10.0 million, primarily due to higher corporate, general and administrative costs related to legal and other business development expenses, and to a lesser extent from non-recurring employee severance costs, personnel cost and board fees.
- Net non-cash stock compensation expense decreased $188,000, from $488,000 to $300,000, primarily due to forfeitures in the third quarter partially offset by higher expense from stock grants issued to employees and the Board of Directors in 2021.
- There was no unrealized gain or loss on our fair value investment for the three months ended September 30, 2021, as compared to an unrealized loss of $3.1 million for the three months ended September 30, 2020. There was no realized gain or loss on our fair value investment for the three months ended September 30, 2021 and 2020. Refer to Note 4 to the consolidated financial statements elsewhere herein for additional information.
- Unrealized gain from the fair value measurements of the Series A and Series B warrants and the embedded derivative decreased to $619,000 for the three months ended September 30, 2021, as compared to an unrealized gain of $20.7 million for the three months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Securities.
- Unrealized gain from equity securities increased to $66.5 million for the three months ended September 30, 2021, as compared to an unrealized gain of $20.5 million for the three months ended September 30, 2020. The current period unrealized gain primarily relates to one Life Sciences Portfolio company’s valuation increase in connection with its initial public offering. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in equity securities.

37

- Realized gain from the sale of our equity securities increased to $37.7 million for the three months ended September 30, 2021, as compared to a gain of $2.7 million for the three months ended September 30, 2020. The current period realized gain primarily relates to the partial sale of two Life Sciences Portfolio securities. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in equity securities.
- We incurred losses on foreign currency exchange of $17,000 and $48,000 during the three months ended September 30, 2021 and 2020, respectively.
- We incurred interest expense of $2.5 million during the three months ended September 30, 2021 from the Notes issued in 2020 and 2021, as compared to $2.4 million during the three months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Senior Secured Notes.
- Interest income and other increased to $76,000 for the three months ended September 30, 2021 from $10,000 for the three months ended September 30, 2020. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our cash and cash equivalents and investments in equity securities.

### Results of Operations – Nine months ended September 30, 2021 compared with the nine months ended September 30, 2020

Revenues decreased $614,000 to $24.8 million for the nine months ended September 30, 2021, as compared to $25.4 million in the comparable prior year, primarily due to a decrease in revenues from licensing and enforcement programs generating revenue during the period. Refer to “*Investments in Patent Portfolios”* above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.

Loss before income taxes was $54.1 million for the nine months ended September 30, 2021, as compared to income before income taxes of $31.9 million for the nine months ended September 30, 2020. The net change was comprised of the change in revenues described above and other changes in operating expenses and other income (expense) as follows:

- Paid-up revenue decreased $1.4 million primarily due to a decrease in average revenue per agreement executed during the period, offset by an increase of $753,000 in recurring revenue that provides for quarterly sales-based license fees. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding certain sales-based revenue contracts that provide for the payment of quarterly license fees based on quarterly sales of applicable product units by licensees.
- Inventor royalties and contingent legal fees, on a combined basis, decreased $7.1 million, from $13.7 million to $6.6 million, primarily due to a higher percentage of revenues generated during the nine months ended September 30, 2021 having no inventor royalty obligations.
- Litigation and licensing expenses - patents increased $1.4 million, from $3.5 million to $4.9 million, primarily due to a net increase in litigation support and third-party technical consulting expenses associated with ongoing litigation.
- Amortization of patents expense increased $3.6 million, from $3.5 million to $7.1 million, due to an increase in scheduled amortization resulting from the new portfolios acquired in 2020 and 2021.
- Other patent portfolio income for the nine months ended September 30, 2020 was $308,000 due to the reversal of previously recorded expenses for settlement and contingency accruals.
- General and administrative expenses, excluding non-cash stock compensation, increased $4.9 million, from $16.8 million to $21.7 million, primarily due to higher corporate, general and administrative costs related to legal and other business development expenses, personnel cost and board fees, and to a lesser extent from increased variable performance-based compensation costs.
- Net non-cash stock compensation expense increased $36,000, from $1.2 million to $1.3 million, primarily due to stock grants issued to employees and the Board of Directors in 2021, partially offset by forfeitures for terminated employees.

38

- We recognized an unrealized loss of $2.8 million on our fair value investment for the nine months ended September 30, 2021, as compared to an unrealized gain of $3.7 million for the nine months ended September 30, 2020. There was a realized gain of $3.6 million on our fair value investment for the nine months ended September 30, 2021, as compared to a realized loss of $2.8 million for the nine months ended September 30, 2020. Refer to Note 4 to the consolidated financial statements elsewhere herein for additional information.
- We incurred an unrealized net loss of $203.9 million from the fair value measurements of the Series A and Series B warrants and the embedded derivative for the nine months ended September 30, 2021, as compared to an unrealized loss of $46.6 million for the nine months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Securities.
- Unrealized gain from equity securities increased to $115.5 million for the nine months ended September 30, 2021, as compared to an unrealized gain of $99.4 million for the nine months ended September 30, 2020. The current period unrealized gain primarily relates to one Life Sciences Portfolio company’s valuation increase in connection with its initial public offering. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment equity securities.
- Realized gain from the sale of our equity securities increased to $53.1 million for the nine months ended September 30, 2021, as compared to a loss of $4.3 million for the nine months ended September 30, 2020. The current period realized gain primarily relates to the sale of three Life Sciences Portfolio securities. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in equity securities.
- Earnings on equity investment in joint venture was $2.7 million for the nine months ended September 30, 2021. Refer to Note 3 to the consolidated financial statements elsewhere herein for additional information regarding our equity method investment.
- We incurred losses on foreign currency exchange of $193,000 and $4.9 million during the nine months ended September 30, 2021 and 2020, respectively.
- We incurred interest expense of $5.6 million during the nine months ended September 30, 2021 from the Notes issued in 2020 and 2021, as compared to $3.2 million during the nine months ended September 30, 2020. Refer to Note 6 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Senior Secured Notes.
- Interest income and other decreased to $135,000 for the nine months ended September 30, 2021 from $811,000 for the nine months ended September 30, 2020, mainly due to a decrease in interest income from our former investment in debt securities, which was sold in 2020. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our cash and cash equivalents and investments in equity securities.

### Revenues

Revenue for the periods presented included the following:

|  | Three Months Ended September 30, 2021 | 2020 | $ Change | % Change | Nine Months Ended September 30, 2021 | 2020 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues (in thousands, except percentage change values) | $1,582 | $19,466 | $(17,884) | (92%) | $24,785 | $25,399 | $(614) | (2%) |
| New agreements executed | 3 | 3 | – | 0% | 16 | 11 | 5 | 45% |
| Licensing and enforcement programs generating revenues | 3 | 5 | (2) | (40%) | 7 | 8 | (1) | (13%) |
| Licensing and enforcement programs with initial revenues | – | 1 | (1) | (100%) | 3 | 2 | 1 | 50% |
| New patent portfolios | – | – | – | 0% | 1 | 4 | (3) | (75%) |

39

For the periods presented herein, the majority of the revenue agreements executed provided for the payment of one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technology rights owned by our operating subsidiaries. These rights were primarily granted on a perpetual basis, extending until the expiration of the underlying patents.

Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our revenue arrangements and related concentrations for the periods presented herein.

Refer to “*Investments in Patent Portfolios”* above for information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.

### Cost of Revenues

#### Inventor Royalties and Contingent Legal Fees Expense

*(In thousands, except percentage change values)*

|  | Three Months Ended September 30, 2021 | 2020 | $ Change | % Change | Nine Months Ended September 30, 2021 | 2020 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Inventor royalties | $280 | $5,772 | $(5,492) | (95%) | $823 | $6,843 | $(6,020) | (88%) |
| Contingent legal fees | 285 | 6,609 | (6,324) | (96%) | 5,735 | 6,855 | (1,120) | (16%) |
| Total | $565 | $12,381 | $(11,816) | (95%) | $6,558 | $13,698 | $(7,140) | (52%) |

For the three months ended September 30, 20201, inventor royalties and contingent legal fees, on a combined basis, decreased $11.8 million, or 95%. For the nine months ended September 30, 20201, inventor royalties and contingent legal fees, on a combined basis, decreased $7.1 million, or 52%. Inventor royalties and contingent legal fee expenses fluctuate from period to period based on the amount of revenues recognized each period, the terms and conditions of agreements executed each period and the mix of specific patent portfolios, with varying economic terms and obligations, generating revenues each period.

#### Litigation and Licensing Expenses - Patents and Amortization of Patents

*(In thousands, except percentage change values)*

|  | Three Months Ended September 30, 2021 | 2020 | $ Change | % Change | Nine Months Ended September 30, 2021 | 2020 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Litigation and licensing expenses - patents | $782 | $1,001 | $(219) | (22%) | $4,881 | $3,497 | $1,384 | 40% |
| Amortization of patents | 2,612 | 1,174 | 1,438 | 122% | 7,086 | 3,522 | 3,564 | 101% |
| Total | $3,394 | $2,175 | $1,219 | 56% | $11,967 | $7,019 | $4,948 | 70% |

For the three months ended September 30, 2021, litigation and licensing expenses-patents decreased $219,000, or 22%. For the nine months ended September 30, 2021, litigation and licensing expenses-patents increased $1.4 million, or 40%. The changes were due to fluctuations in litigation support and third-party technical consulting expenses during the periods presented.

For the three months ended September 30, 2021, amortization expense increased $1.4 million, or 122%. For the nine months ended September 30, 2021, amortization expense increased $3.6 million, or 101%. These increases were due to new patents acquired in 2020 and 2021.

### Operating Expenses

#### General and Administrative Expenses

*(In thousands, except percentage change values)*

|  | Three Months Ended September 30, 2021 | 2020 | $ Change | % Change | Nine Months Ended September 30, 2021 | 2020 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| General and administrative expenses | $10,045 | $7,204 | $2,841 | 39% | $21,735 | $16,846 | $4,889 | 29% |
| Non-cash stock compensation expense | 300 | 488 | (188) | (39%) | 1,279 | 1,243 | 36 | 3% |
| Total general and administrative expenses | $10,345 | $7,692 | $2,653 | 34% | $23,014 | $18,089 | $4,925 | 27% |

A summary of the main drivers of the change in general and administrative expenses for the periods presented, is as follows:

*(In thousands)*

|  | Three Months Ended September 30, 2021 vs. 2020 | Nine Months Ended September 30, 2021 vs. 2020 |
| --- | ---: | ---: |
| Personnel costs and board fees | $415 | $1,563 |
| Variable performance-based compensation costs | (172) | 268 |
| Corporate, general and administrative costs | 2,111 | 2,973 |
| Non-cash stock compensation expense | (188) | 36 |
| Non-recurring employee severance costs | 487 | 85 |
| Total change in general and administrative expenses | $2,653 | $4,925 |

The increases in personnel cost and board fees for the periods presented were primarily due to an increase in headcount and related costs. The changes in variable performance-based compensation costs were primarily due to fluctuations in performance-based compensation accruals. The increases in corporate, general and administrative costs were primarily due to higher legal and business development related expenses. The decrease in non-cash stock compensation expense for the three months ended September 30, 2021, was primarily due to forfeitures in the third quarter partially offset by higher expense from stock grants issued to employees and the Board of Directors in 2021. Non-recurring employee severance costs fluctuate based on the severance arrangements of terminated employees.

### Other Income (Expense)

Our equity investments in Veritone, the Life Sciences Portfolio and other equity securities are recorded at fair value at each balance sheet date.

Our quarterly results included no unrealized or realized gain or loss on our fair value investment in Veritone for the three months ended September 30, 2021, as compared to an unrealized loss of $3.1 million for the three months ended September 30, 2020. Our year-to-date results included an unrealized loss of $2.8 million on our fair value investment in Veritone for the nine months ended September 30, 2021, as compared to an unrealized gain of $3.7 million for the nine months ended September 30, 2020. There was a realized gain of $3.6 million on our equity investment in Veritone for the nine months ended September 30, 2021, as compared to a realized loss of $2.8 million for the nine months ended September 30, 2020. Refer to Note 4 to the consolidated financial statements elsewhere herein for additional information regarding our investment in Veritone.

Our quarterly results included an unrealized gain from equity securities of $66.5 million for the three months ended September 30, 2021, as compared to an unrealized gain of $20.5 million for the three months ended September 30, 2020. Realized gain from the sale of our equity securities increased to $37.7 million for the three months ended September 30, 2021, as compared to a gain of $2.7 million for the three months ended September 30, 2020. Our year-to-date results included an unrealized gain from equity securities of $115.5 million for the nine months ended September 30, 2021, as compared to an unrealized gain of $99.4 million for the nine months ended September 30, 2020. Realized gain from the sale of our equity securities increased to $53.1 million for the nine months ended September 30, 2021, as compared to a loss of $4.3 million for the nine months ended September 30, 2020. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in the Life Sciences Portfolio and other equity securities.

### Income Taxes

*(In thousands, except percentage values)*

|  | Three Months Ended September 30, 2021 | 2020 | $ Change | % Change | Nine Months Ended September 30, 2021 | 2020 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Income tax (expense) benefit | $(11) | $(83) | $72 | (87%) | $(531) | $1,257 | $(1,788) | (142%) |
| Effective tax rate | 0% | 0% | – | 0% | (1%) | (4%) | – | 3% |

The provision for income taxes is determined using an effective tax rate. For the three and nine months ended September 30, 2021, the Company’s estimated annual effective tax rates were lower than the U.S. federal statutory rate primarily due to the change in valuation allowance, as well as state income taxes. The effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions used to estimate the effective tax rate, including factors such as expected utilization of net operating loss carryforwards, changes in or the interpretation of tax laws in jurisdictions where the Company conducts business, the Company’s expansion into new states or foreign countries, and the amount of valuation allowances against deferred tax assets. For the nine months ended September 30, 2020, the Company recorded a benefit for income taxes of which primarily reflects the impact of state taxes and foreign tax withholding or refund incurred on revenue agreements executed with third-party licensees domiciled in foreign jurisdictions.

The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities along with net operating loss and tax credit carryforwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. For the nine months ended September 30, 2021, the Company has recorded a full valuation allowance against its deferred tax assets as they are not expected to be realized.

On March 27, 2020, the United States enacted the CARES Act which provides certain income tax benefits including the ability to carryback federal NOLs generated in 2018 through 2020 for an extended five-year period and increased the limitation for the deduction of interest expense from 30 percent to 50 percent of modified taxable income. The CARES Act also provides other economic benefits such as allowing employers to defer payment of the employer’s portion of payroll taxes for 2020 and a refundable employee retention credit of up to $5,000 per eligible employee wages. The Company did not realize benefits from the provisions of the CARES Act including the extended NOL carryback period, the payroll tax deferral, and the employee retention credit.

On December 27, 2020, the United States enacted the Consolidated Appropriations Act which extended many of the benefits of the CARES Act that were scheduled to expire. The Company does not expect a material impact of Consolidated Appropriations Act on its consolidated financial statements and related disclosures.

On March 11, 2021 the United States enacted the American Rescue Plan Act of 2021. These Acts includes various income and payroll tax measures. The Company does not expect a material impact of the American Rescue Plan on its consolidated financial statements and related disclosures.

On June 29, 2020, the state of California passed Assembly Bill 85 which suspends the California net operating loss deduction for the 2020-2022 tax years and the R&D credit usage for the same period (for credit usages in excess of $5.0 million). The Company anticipates a California income tax liability for 2021, however it is not expected to materially impact the consolidated financial statements.

### Liquidity and Capital Resources

#### General

Our primary sources of liquidity are cash and cash equivalents on hand generated from our operating activities, and as deemed appropriate by management from our Senior Secured Notes (discussed below under the caption “Starboard Investment and Senior Secured Notes”). Our management believes that our cash and cash equivalent balances, anticipated cash flows from operations and proceeds from our Senior Secured Notes will be sufficient to meet our cash requirements through at least twelve months from the date of this report and for the foreseeable future. We may, however, encounter unforeseen difficulties that may deplete our capital resources more rapidly than anticipated, including those set forth under Part II, Item 1A, “Risk Factors”. Any efforts to seek additional funding could be made through issuances of equity or debt, or other external financing. However, additional funding may not be available to us on favorable terms, or at all. The capital and credit markets have experienced extreme volatility and disruption in recent years, and the volatility and impact of the disruption may continue. At times during this period, the volatility and disruption has reached unprecedented levels. In several cases, the markets have exerted downward pressure on stock prices and credit capacity for certain issuers, and the commercial paper markets may not be a reliable source of short-term financing for us. If we fail to obtain additional financing when needed, we may not be able to execute our business plans and our business, conducted by our operating subsidiaries, may suffer.

Certain of our operating subsidiaries are often required to engage in litigation to enforce their patents and patent rights. In connection with any of our operating subsidiaries’ patent enforcement actions, it is possible that a defendant may request and/or a court may rule that an operating subsidiary has violated statutory authority, regulatory authority, federal rules, local court rules, or governing standards relating to the substantive or procedural aspects of such enforcement actions. In such event, a court may issue monetary sanctions against us or our operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material.

#### Cash, Cash Equivalents and Investments

Our consolidated cash, cash equivalents, equity securities at fair value, and long-term restricted cash totaled $640.5 million at September 30, 2021, compared to $309.6 million at December 31, 2020.

The net change in cash, cash equivalents and restricted cash for the periods presented was comprised of the following:

*(In thousands)*

| Net cash (used in) provided by: | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: |
| Operating activities | $(7,602) | $5,549 |
| Investing activities | (3,219) | (9,815) |
| Financing activities | 64,417 | 109,471 |
| Increase in cash and cash equivalents and restricted cash | $53,596 | $105,205 |

#### Cash Flows from Operating Activities

Cash receipts from licensees for the nine months ended September 30, 2021 decreased to $24.9 million, as compared to $25.6 million in the comparable 2020 period, mainly due to the timing on cash collected from accounts receivables in prior year.

Cash outflows from operations for the nine months ended September 30, 2021 increased to $7.6 million, as compared to a $5.5 million cash inflow in the comparable 2020 period, primarily due to our higher net loss (discussed above under the caption “Results of Operations – Nine months ended September 30, 2021 compared with the nine months ended September 30, 2020”) and a gain on sale of equity securities, partially offset by the net changes in fair value of Series A and B warrants, embedded derivatives and equity securities and to a lesser extent the changes in working capital cash flows. Refer to “Working Capital” below for additional information.

#### Cash Flows from Investing Activities

Cash flows from investing activities and related changes were comprised of the following for the periods presented:

*(In thousands)*

|  | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: |
| Patent acquisition | $(13,000) | $(13,780) |
| Sale of investment at fair value | 3,591 | 1,460 |
| Purchases of equity securities | (57,978) | (33,800) |
| Maturities and sales of equity securities | 64,235 | 316,746 |
| Purchases of prepaid investment | – | (276,275) |
| Equity securities derivative and forward contract acquisition cost | – | (3,989) |
| Purchases of property and equipment | (67) | (177) |
| Net cash used in investing activities | $(3,219) | $(9,815) |

#### Cash Flows from Financing Activities

Cash flows from financing activities and related changes were comprised of the following for the periods presented:

*(In thousands)*

|  | Nine Months Ended September 30, 2021 | 2020 |
| --- | ---: | ---: |
| Repurchase of common stock | $– | $(3,998) |
| Issuance of Senior Secured Notes, net of lender fee | 65,000 | 110,437 |
| Senior Secured Notes issuance costs paid to other parties | – | (496) |
| Dividend on Series A Redeemable Convertible Preferred Stock | (785) | (1,120) |
| Issuance of Series B warrants | – | 4,600 |
| Proceeds from exercise of stock options | 202 | 48 |
| Paydown of Senior Secured Notes - short-term | (50,000) | – |
| Reissuance of Senior Secured Notes - short-term | 50,000 | – |
| Net cash provided by financing activities | $64,417 | $109,471 |

#### Starboard Investment and Senior Secured Notes

On November 18, 2019, the Company entered into the Securities Purchase Agreement with Starboard and the Buyers pursuant to which the Buyers purchased (i) 350,000 shares of Series A Preferred Stock at an aggregate purchase price of $35.0 million, and Series A Warrants to purchase up to 5 million shares of the Company’s common stock.

On February 25, 2020, pursuant to the terms of the Securities Purchase Agreement with Starboard and the Buyers, the Company issued Series B Warrants to purchase up to 100 million shares of the Company’s common stock at an exercise price of either (i) $5.25 per share, if exercising by cash payment, or (ii) $3.65 per share, if exercising by cancellation of a portion of Notes. The Company issued the Series B Warrants for an aggregate purchase price of $4.6 million.

On June 4, 2020, pursuant to the Securities Purchase Agreement dated November 2019, the Company issued $115.0 million in Notes to the Buyer. Per the Supplemental Agreement, interest is payable semiannually at a rate of 6.00% per annum, and in an event of default, the interest rate is increased to 10.00% per annum. In connection with the issuance of the Notes, the terms of certain of the Series B Warrants were amended to permit the payment of the lower exercise price of $3.65 through the payment of cash, rather than only through the cancellation of Notes outstanding, at any time until the expiration date of November 15, 2027. 31,506,849 of the Series B Warrants are subject to this adjustment with the remaining balance of 68,493,151 Series B Warrants continuing under their original terms.

On June 30, 2020, the Company entered into the Exchange Agreement with Merton and Starboard, on behalf of itself and on behalf of certain funds and accounts under its management, including the holders of the Notes. Pursuant to the Exchange Agreement, the holders of the Notes exchanged the entire outstanding principal amount for New Notes issued by Merton having an aggregate outstanding original principal amount of $115.0 million.

On January 29, 2021, the Company redeemed $50.0 million of the New Notes and on March 31, 2021, the Company reissued $50.0 million of the New Notes. On June 30, 2021, the Company issued $30.0 million in additional New Notes (the “June 2021 Merton Notes”) and amended the maturity date of the New Notes to October 15, 2021. On September 30, 2021, the Company issued $35.0 million in additional New Notes (the “September 2021 Merton Notes”) and amended the maturity date of the New Notes to December 1, 2021. The June and September 2021 Merton Notes cannot be used to exercise Series B Warrants issued to Starboard Value. The total principal amount outstanding of New Notes as of September 30, 2021 and December 31, 2020 was $180.0 million and $115.0 million, respectively.

Refer to Notes 2 and 6 to the consolidated financial statements elsewhere herein for additional information related to the Starboard Securities and Senior Secured Notes.

#### Working Capital

Working capital at September 30, 2021 increased to $465.0 million, as compared to $332.9 million at December 31, 2020. Accounts receivable from licensees decreased to $412,000 at September 30, 2021, compared to $506,000 at December 31, 2020. Accounts payable, accrued expenses and accrued compensation increased to $11.8 million at September 30, 2021, from $7.0 million at December 31, 2020. Royalties and contingent legal fees payable decreased to $1.8 million at September 30, 2021, from $2.2 million at December 31, 2020.

The royalties and contingent legal fees payable are generally scheduled to be paid in the subsequent quarter upon our receipt of the related fee payments from licensees, in accordance with the underlying contractual arrangements.

### Critical Accounting Policies and Estimates

Our unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Preparation of these condensed consolidated statements requires management to make assumptions, judgments and estimates that can have a significant impact on amounts reported in these condensed consolidated financial statements. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.

The Securities and Exchange Commission (“SEC”) has defined a company’s critical accounting policies as the ones that are most important to the portrayal of a company’s financial condition and results of operations, and which require a company to make its most difficult and subjective judgments. A summary of significant accounting policies and a description of accounting policies that are considered critical may be found in the audited consolidated financial statements and notes thereto and under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies” included in our Annual Report. In addition, as set forth in Note 2 (under the caption “Use of Estimates”) to the consolidated financial statements included in this report, certain accounting policies were identified during the current period, based on activities occurring during the current period, as critical and requiring significant judgments and estimates.

### Recently Adopted Accounting Pronouncements

Refer to Note 2 (under the caption “Recent Accounting Pronouncements”) to the consolidated financial statements included in this report for additional information.

### Off-Balance Sheet Arrangements

As of September 30, 2021, we did not have any relationships with any unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established to facilitate any off-balance sheet arrangements or for any other contractually specified purposes.

## Market risk

As filed, 3,435 characters.

The primary objective of our short-term investment activities is to preserve principal while concurrently maximizing the income we receive from our equity securities at fair value without significantly increasing risk. Some of the securities that we invest in may be subject to interest rate risk and/or market risk. This means that a change in prevailing interest rates, with respect to interest rate risk, or a change in the value of the United States equity markets, with respect to market risk, may cause the principal amount or market value of the equity securities at fair value to fluctuate. For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the prevailing interest rate later rises, the current value of the principal amount of our investment may decline. To minimize these risks in the future, we intend to maintain our portfolio of cash equivalents and equity securities at fair value in a variety of securities, including commercial paper, money market funds, government and non-government debt securities, certificates of deposit and equity securities. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate. Accordingly, a 100 basis point increase in interest rates or a 10% decline in the value of the United States equity markets would not be expected to have a material impact on the value of such money market funds. Declines in interest rates over time will, however, reduce our interest income.

During 2020, we sold all of our investment in debt securities, comprised of AAA rated money market funds that invested in first-tier only securities, which primarily included domestic commercial paper, securities issued or guaranteed by the U.S. government or its agencies, U.S. bank obligations and fully collateralized repurchase agreements, and direct investments in short-term, highly liquid, investment grade, U.S. government and corporate securities.

#### Investment Risk

We are exposed to investment risks related to changes in the underlying financial condition of certain of our equity investments in technology companies. The fair value of these investments can be significantly impacted by the risk of adverse changes in securities markets generally, as well as risks related to the performance of the companies whose securities we have invested in, risks associated with specific industries, and other factors. These investments are subject to significant fluctuations in fair value due to the volatility of the securities markets and of the underlying businesses.

As of September 30, 2021 and December 31, 2020, the carrying value of our common stock and warrants in public and private companies was $424.8 million and $285.8 million, respectively.

#### Foreign Currency Exchange Risk

Although we do not have any material foreign operations, we are also exposed to market risks related to fluctuations in foreign currency exchange rates between the U.S. dollar, and the British Pound and Euro currency exchange rates, primarily related to revenue agreements with licensees domiciled in foreign jurisdictions and certain equity security investments. A hypothetical 10% change in exchange rates related to our at risk foreign denominated equity securities would have approximately a $32.4 million effect on our financial position and results of operations.

## Controls and procedures

As filed, 2,657 characters.

#### (i). Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2021, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure, and that such information is recorded, processed, summarized and reported within the time periods prescribed by the SEC.

#### (ii). Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during our last fiscal quarter (the quarter ended September 30, 2021) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### (iii). Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of the effectiveness of controls to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

## Risk factors

As filed, 3,003 characters.

An investment in our common stock involves risks. Before making an investment decision, you should carefully consider all of the information in this Quarterly Report on Form 10-Q, including in the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part I, Item 2, as well as our consolidated financial statements and the accompanying notes thereto. In addition, you should carefully consider the risks and uncertainties described below, and in the section entitled “Risk Factors” in Part I, Item 1A of our Annual Report, as well as in our other public filings with the SEC. If any of the identified risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that case, the trading price of our common stock may decline, and you could lose all or part of your investment. In addition, other risks of which we are currently unaware, or which we do not currently view as material, could have a material adverse effect on our business, financial condition, operating results and prospects.

### Risks related to COVID-19

***The COVID-19 pandemic could have a material adverse effect on our operations, the operations of our business partners, and the global economy as a whole.***

The ongoing COVID-19 pandemic, and governmental and societal responses thereto, have had a severe impact on recent global economic and market conditions, including significant disruption of, and volatility in, financial markets, global supply chain, and the institution of social distancing and shelter-in-place requirements that have resulted in temporary closures of many businesses, lost revenues, and increased unemployment.

These conditions could adversely impact our operations, as well as the operations of our licensees and other business partners. With regard to the COVID-19 pandemic, we do not expect the current situation to present direct risks to our business. Our cash is held in major financial institutions primarily in government instruments. Our business is fully able to operate in a socially distanced and/or remote capacity and in accordance with applicable laws, policies, and best practices. Our workforce is provided ample paid sick leave, and we have in place robust disaster recovery and business continuity policies that have been revised to account for a long-term remote work contingency such as this. While governmental authorities have taken measures to provide economic assistance to individual households and businesses, stabilize the markets, and support economic growth, the ultimate success of these measures is unknown and they may not be sufficient to mitigate fully the negative impact of the ongoing pandemic. However, the ongoing pandemic may present risks that we do not currently consider material or risks that may evolve quickly that could have a materially adverse effect on our business, financial condition, operating results, and/or prospects.

Filed Nov 15, 2021.
Source: SEC EDGAR, the filing index for accession 0001683168-21-005701. Last ingested by Listed: Nov 6, 2026, 16:47 ET. No prices; not investment advice.
